As a result, we are further upgrading our full-year guidance to reflect this performance." Full-year 2025 guidanceBased on the strong performance in the third quarter, Ipsen further upgrades its financial guidance for 2025:Total sales growth of around 10.0%, at CER (prior guidance greater than 7.0%). On 23 July 2025, Ipsen received European Commission approval for Cabometyx® (cabozantinib) in previously treated advanced neuroendocrine tumors (NETs), based on positive outcomes from the Phase III CABINET trial. Business developmentOn 22 October 2025 Ipsen announced a definitive share purchase agreement to acquire ImCheck Therapeutics, a private French biotechnology company pioneering next-generation immuno-oncology therapies. 2 Based on the average level of exchange rates in September 2025, an adverse impact on total sales of around 3% from currencies is expected.